Drug development – The success of orphan drugs

Obtaining market approval is the ultimate goal for drug development companies - but few cross that finish line. However, over the past decade, there has been a positive trend in approval rates, especially for drugs that reach clinical phase III. The trend is particularly strong in one specific category – orphan drugs. This fifth and final part of BioStock's article series on drug development takes a closer look at orphan drug designation and its benefits, as well as some of its shortcomings.

Read the article at biostock.se:

https://www.biostock.se/en/2023/01/drug-development-the-success-of-orphan-drugs/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/